9 results · 20ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

SAFECARE Multi-Drug Urine Test Cup, SAFECARE Multi-Drug Urine Test Dip Card

FDA 510(k)
FDA Class 2 ·Clinical Toxicology

ENTERAL ONLY EXTENSION SET

FDA 510(k)
FDA Class 2 ·Gastroenterology, Urology

VERTEX RAPID SIMPLIFIED

FDA 510(k)
FDA Class 2 ·Dental

BD SYRINGE 60ML ST

FDA Adverse Event
Malfunction ·BD MEDICAL (BD WEST) MEDICAL SURGICAL·Product code FMF·October 20, 2021

6000CMS

FDA Adverse Event
Malfunction ·MOOG DEVICE GROUP·Product code FRN·June 11, 2013

OT ULTRALINK METER

FDA Adverse Event
Malfunction ·LIFESCAN INC.·Product code NBW·July 28, 2011

OXIMAX N-595 PULSE OXIMETER

FDA Adverse Event
Malfunction ·COVIDIEN FORMERLY TYCO HEALTHCARE·Product code DQA·September 24, 2008

BD¿ SYRINGE 60 ML LUER SLIP TIP

FDA Adverse Event
Malfunction ·BD MEDICAL (BD WEST) MEDICAL SURGICAL·Product code FMF·February 24, 2022

Boston Scientific COGNIS CRT-D, Cardiac Resynchronization Therapy Defibrillator, models N118, N119. The following models are not available in the US: models N106, N107, P106, P107. Sterilized using ethylene oxide. Product Usage: Boston Scientific cardiac resynchronization therapy defibrillators (CRT-Ds) are indicated for patients with moderate to severe heart failure who remain symptomatic despite stable, optimal heart failure drug therapy and have left ventricular dysfunction and QRS duration > or equal to 120 ms. This family of pulse generators provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Cardiac Resynchronization Therapy (CRT), which treats heart failure by resynchronizing ventricular contractions through biventricular electrical stimulation; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy.

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014